As discussed in my Aug. 25 commentary, biologics are poised to assume a major role in the treatment of patients with potential or actual vision loss from congenital or acquired eye diseases and ocular degenerations.
In review, a biologic is a therapeutic agent that is a living cell, is a component of a living cell such as a gene, or is produced by a living cell such as a secretome or protein. A biologic used in therapy is a biotherapeutic. FDA approval of biologics in the U.S. is under the direction of the Center for Biologics Evaluation and Research (CBER). Extensive data, including